The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | The current SoC for patients with primary CNS lymphoma
Lakshmi Nayak, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the current standard of care (SoC) in patients with primary central nervous system (CNS) lymphoma, which includes two phases, induction followed by consolidation. Induction chemotherapy often involves high-dose methotrexate-based regimens aiming to achieve complete response (CR). For consolidation, there are three main regimens: autologous stem cell transplantation (autoSCT) for young and fit patients, whole brain radiation, or chemotherapy. Dr Nayak hopes novel therapies being investigated in the relapsed/refractory (R/R) setting will be brought into frontline treatment to reduce recurrence. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
